The company reported drops in revenues for both its human health and environmental health units, blaming challenging market conditions for the decreases.
Several academic and commercial groups are developing clinical cell-based noninvasive prenatal tests, which could eventually compete with current cell-free NIPTs.
The company said the diagnostics unit will be focused on reproductive health, diagnostics for emerging markets, and applied genomics.
The company said it will use the proceeds for various purposes, including working capital, capital expenditures, stock repurchases, dividends, and acquisitions.
Revenues rose thank to an increase in the company's human health business, which offset a decline in its environmental health segment.
The 10-year notes were rated BBB by Fitch, which also declared the ratings outlook Stable.
The company beat analyst expectations for both revenues and adjusted earnings per share for the quarter.
The company said selling this business unit frees it to focus on developing new maternal and fetal health solutions for the US and elsewhere.
The company's fourth quarter revenues dropped by less than 1 percent compared to the same period last year, but missed analyst estimates.
The company has been quietly working on a fully automated NIPT for trisomies 21, 13, and 18 that requires neither next-gen sequencing nor microarray technology.
New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.
A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.
Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.
In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.